Competitive Advantages
- Potent anti-malarial activity
- Improved chemical resistance against multi-drug resistant (MDR) parasites
- Acts on both MDR parasites and drug susceptible anti-malarial strains equally well
Summary
This invention promises a great approach to treat those affected with malaria. The compound possesses a potent EC50 against mul-tidrug resistant malarial strains W2 (chloroquine and pyrimetham-ine resistant) and TM90-C2B (chloroquine, mefloquine, py-rimethamine, and atovaquone resistant). This compound also ex-hibits signs of reduced chemical resistance.
Plasmodium Species
Desired Partnerships
- License
- Sponsored Research
- Co-Development